<DOC>
	<DOC>NCT02377713</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose in Japanese patients with Mild to Moderate Alzheimer's Disease.</brief_summary>
	<brief_title>A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients with mild to moderate Alzheimer's Disease Body weight ≥ 40 kg and &lt; 100 kg Clinical Dementia Rating (CDR) score of 1 or 2 Mini Mental State Examination (MMSE) score of ≥ 17 amd ≤ 26 Previous active treatment with an Alzheimer's Disease immunotherapy in an investigational study Use of another investigational drug within 4 months prior to the enrollment Subjects who meet National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia Subjects with a history of presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease Subjects with a presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's Alzheimer's Disease Subjects who have evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than Alzheimer's Disease</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>KHK6640</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Japanese</keyword>
	<keyword>single dose</keyword>
	<keyword>Alzheimer's disease</keyword>
</DOC>